Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Clinical Trial ID NCT00021255

PubWeight™ 21.64^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00021255

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Adjuvant trastuzumab in HER2-positive breast cancer.	N Engl J Med	2011	12.52
2	Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.	J Clin Oncol	2010	2.48
3	Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).	Breast Cancer Res Treat	2013	1.34
4	Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.	MAbs	2011	1.08
5	Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.	Biochim Biophys Acta	2014	0.96
6	PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.	Clin Cancer Res	2015	0.81
7	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.	J Clin Oncol	2016	0.80
8	Targeted Therapies in HER2-Positive Breast Cancer - a Systematic Review.	Breast Care (Basel)	2015	0.77
9	Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.	Oncologist	2013	0.77
10	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.	Ther Adv Med Oncol	2016	0.75